Brexpiprazole

Overview

Brexpiprazole (OPC-34712), an atypical orally active antipsychotic agent, is a partial agonist of human 5-HT1A and dopamine D 2L receptor with K i s of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a 5-HT2A receptor antagonist with a K i of 0.47 nM. Brexpiprazole also shows potent antagonist activity at human noradrenergic α 1B (K i =0.17 nM) and α 2C receptors (K i =0.59 nM).

Application

Products | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Depression | Products > Disease Areas > Alzheimer's Disease | Products > Disease Areas > Parkinson's Disease | Products > Disease Areas > Obesity | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Neuronal Signaling | Products > Research Areas > Neurological Disease | Products > Signaling Pathways > 5-HT Receptor | Products > Signaling Pathways > Dopamine Receptor | Products > Signaling Pathways > Adrenergic Receptor

Product Information

• Catalog No.: HY-15780
• CAS No.: 913611-97-9
• Molecular Formula: C25H27N3O2S
• Molecular Weight: 433.57
• Purity: 99.80%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: 2.5 mg/mL (5.77 mM); Suspended solution; Need ultrasonic
• Availability: In-stock

Source

Original product source